Dermatologic Therapy最新文献

{"title":"Review of Biological Agents in the Therapeutic Management of Monogenic Genodermatoses","authors":"Xueying Wang,&nbsp;Qing Zhao,&nbsp;Hong Liu,&nbsp;Furen Zhang","doi":"10.1155/dth/5422922","DOIUrl":"https://doi.org/10.1155/dth/5422922","url":null,"abstract":"<p>Monogenic genodermatoses encompass a diverse group of over 400 distinct disorders, presenting significant therapeutic challenges. Recent advancements in the clinical application of biological agents have heralded a new era in the management of these conditions. A plethora of clinical studies and case reports have demonstrated the efficacy of TNF-α, IL-1, IL-4Rα, IL-17A, IL-12/23, and IL-6R inhibitors in the management of monogenic genodermatoses. To elucidate the current landscape of biological agent utilization and their putative mechanisms of action in the context of monogenic genodermatoses, we conducted a review of the literature.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5422922","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Enhanced Effect of Q-Switched Nd:YAG Laser (1064-nm) Combined With Glycolic Acid on Keratosis Pilaris: A Split-Body Randomized Clinical Trial","authors":"Man Li,&nbsp;Xiaoduo Liu,&nbsp;Ruofei Yuan,&nbsp;Yue Bai,&nbsp;Zhixuan Duan,&nbsp;Yi Liu,&nbsp;Xuelei Liang,&nbsp;Haixuan Wu,&nbsp;Fenglin Zhuo","doi":"10.1155/dth/1491351","DOIUrl":"https://doi.org/10.1155/dth/1491351","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The Q-switched Nd:YAG laser (1064-nm) has been reported to be the best choice for keratosis pilaris (KP) with a high frequency of treatment. Glycolic acid (GA) is known to correct abnormal keratinization and accelerate melanin metabolism. However, the combined effect of Q-switched Nd:YAG laser (1064-nm) and GA on KP has not been studied.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the efficacy and safety of combining Q-switched Nd:YAG laser (1064-nm) with 30% GA in the treatment of KP.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This prospective, rater-blinded split-body comparative study was conducted on patients with bilateral KP on their upper arm. Each participant’s arms were randomly assigned to either the combination group (treated with 30% GA followed by Q-switched Nd:YAG laser) or the control group (treated with Q-switched Nd:YAG laser alone). Treatments were administered in four sessions, 3 weeks apart. The primary endpoint was the difference in average physicians’ assessment scores between groups. The secondary endpoints were the patients’ self-assessment scores, dermoscopic and ultrasonographic improvements, and adverse effects. Clinical, dermoscopic, and ultrasonographic assessments were conducted at baseline and 4 weeks after the final treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 22 patients completed the study. Physicians’ assessment indicated significant improvements in both roughness and redness scores from baseline to final follow-up in both groups (all &lt;i&gt;p&lt;/i&gt; &lt; 0.01). In between-group comparisons, both physician and patient assessments demonstrated significantly superior improvement in the combination group for roughness, redness, and overall scores compared to the control group (all &lt;i&gt;p&lt;/i&gt; &lt; 0.01). Regarding objective measurements, dermoscopic examination showed no significant intergroup differences in the perifollicular erythema and hyperpigmentation (both &lt;i&gt;p&lt;/i&gt; &gt; 0.05). However, the combination group led to significantly greater improvement in follicular plugs and, on high-frequency ultrasound, in the number of epidermal bulges (both &lt;i&gt;p&lt;/i&gt; &lt; 0.05). No severe adverse effects were reported in either group.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The combined therapy of Q-switched Nd:YAG laser (1064-nm) and 30% GA has the enhanced effect in treating KP, offering significant improvements in skin texture with a favorable safety profile.&lt;","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1491351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147562786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution and Future Development Trends of Focused Ultrasound Technology in Aesthetics","authors":"Fujia Sun,&nbsp;Yu Xia,&nbsp;Huaqing Lei,&nbsp;Hengqing Cui,&nbsp;Shuqi Wang,&nbsp;Wenjun Zhang","doi":"10.1155/dth/6633417","DOIUrl":"10.1155/dth/6633417","url":null,"abstract":"<p>Focused ultrasound (FUS) is a noninvasive treatment that has demonstrated significant efficacy in medical aesthetics, particularly in skin tightening, body contouring, and fat reduction. A literature search was conducted on the application of FUS technology in medical aesthetics from 2006 to 2024 using databases such as PubMed, Web of Science, Medline, and Embase. Search terms included “FUS,” “high-intensity focused ultrasound (HIFU),” “microfocused ultrasound (MUS),” “skin tightening,” “skin rejuvenation,” “facial rejuvenation,” and “fat reduction.” The bibliometric analysis identifies key research hotspots and trends in FUS technology, highlighting the United States leadership in the field and the frequent appearance of keywords, such as safety, efficacy, and skin tightening. This review also provides an in-depth discussion on the development of FUS aesthetic devices, including the introduction of the Ulthera system, innovations in skin-tightening devices, and the application of FUS in lipolysis and body contouring. Finally, the review discusses future trends in FUS technology, including advances in real-time imaging, energy focus optimization, and automated intelligent operation. In conclusion, FUS technology has become a crucial tool in aesthetic medicine due to its remarkable clinical results and favorable safety profile, with significant potential for further development.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6633417","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147569955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Systematic Review","authors":"Anna Zygmunt,&nbsp;Anna Mandecka,&nbsp;Łukasz Karoń,&nbsp;Szymon Leonik,&nbsp;Wiktor Kruczek,&nbsp;Aleksandra Frątczak,&nbsp;Beata Bergler-Czop","doi":"10.1155/dth/8862069","DOIUrl":"10.1155/dth/8862069","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Androgenetic alopecia involves the gradual miniaturization of hair follicles, resulting in progressive hair loss. Despite its prevalence, it remains a therapeutic challenge. Current treatments, such as minoxidil and oral finasteride, have limitations. Botulinum toxin type A (BTXA) offers a complementary approach by relaxing scalp muscles, potentially improving blood flow and prolonging hair follicle lifespan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This review aims to evaluate the therapeutic potential of BTXA in AGA treatment by analyzing recent literature. The primary focus is to assess BTXA’s effectiveness, underlying mechanisms, and safety as an adjunctive therapeutic option.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of PubMed identified studies on BTXA for AGA from the database’s inception to December 2024. Emtree and MeSH terms such as “Botulinum Toxins, Type A” and “Androgenetic Alopecia” were used along with additional combinations designed to thoroughly identify relevant studies in the field. Eleven studies met PRISMA guidelines and predefined inclusion and exclusion criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>BTXA treatment proved effective in androgenetic alopecia, increasing hair density by 13%–20% within 12–24 weeks (<i>p</i> &lt; 0.05) and improving follicle diameter by 3 months (<i>p</i> &lt; 0.001). It reduced DHT-induced apoptosis in dermal papilla cells via anti-inflammatory mechanisms and improved seborrhea and scalp vascularization with no significant adverse effects, supporting its role as a safe adjunctive therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>BTXA improves hair density and follicle health in AGA through enhanced vascular dynamics and anti-inflammatory actions. It is a promising adjunctive therapy requiring further studies to refine protocols and assess long-term outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8862069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147569995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of CT-P43, a Candidate Ustekinumab Biosimilar, in Moderate-to-Severe Plaque Psoriasis: 52-Week Results From a Randomised, Active-Controlled, Double-Blind, Phase III Study","authors":"Kim A. Papp,&nbsp;Janusz Jaworski,&nbsp;Bartlomiej Kwiek,&nbsp;Jakub Trefler,&nbsp;Anna Dudek,&nbsp;Jacek C. Szepietowski,&nbsp;Nataliya Reznichenko,&nbsp;Joanna Narbutt,&nbsp;Wojciech Baran,&nbsp;Joanna Kolinek,&nbsp;Stefan Daniluk,&nbsp;Katarzyna Bartnicka-Maslowska,&nbsp;Adam Reich,&nbsp;Yuriy Andrashko,&nbsp;Sunghyun Kim,&nbsp;Yunju Bae,&nbsp;Dabee Jeon,&nbsp;Jinsun Jung,&nbsp;Hyunseung Lee,&nbsp;Woori Ko,&nbsp;YeJin Kim,&nbsp;Diamant Thaçi","doi":"10.1155/dth/8811546","DOIUrl":"https://doi.org/10.1155/dth/8811546","url":null,"abstract":"<p>Equivalent efficacy—mean per cent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week (W) 12 (primary endpoint)—was demonstrated between CT-P43, a candidate ustekinumab biosimilar, and reference ustekinumab. This study further evaluated the efficacy, pharmacokinetics, safety and immunogenicity of CT-P43 vs. reference ustekinumab, including after switching to CT-P43 from reference ustekinumab, in patients with moderate-to-severe plaque psoriasis. In this double-blind Phase III trial, patients were randomised (1:1) to treatment with subcutaneous CT-P43 or reference ustekinumab (45/90 mg [baseline body weight ≤ 100/&gt; 100 kg]). At W16, patients receiving reference ustekinumab were re-randomised (1:1) to either continue this treatment or switch to CT-P43; CT-P43-treated patients continued CT-P43. Study medication was administered at W16 (after re-randomisation), W28 and W40. Secondary efficacy endpoints, pharmacokinetics, safety and immunogenicity were evaluated until W52. At W16, 502 patients were re-randomised (<i>n</i> = 253 continued receiving CT-P43; <i>n</i> = 125 continued receiving reference ustekinumab; <i>n</i> = 124 switched to CT-P43). Mean (standard deviation) PASI scores at W52 were similar across groups (continuing CT-P43: 1.44 [2.921]; continuing reference ustekinumab: 1.33 [3.070]; switched: 1.93 [2.966]). At W52, similar proportions of patients continuing CT-P43, continuing reference ustekinumab and switching achieved ≥ 75% improvement in PASI score (<i>n</i> = 226 [89.3%], 116 [92.8%] and 111 [89.5%]), static Physician’s Global Assessment score of 0/1 (<i>n</i> = 215 [85.0%], 110 [88.0%] and 96 [77.4%]) and Dermatology Life Quality Index score of 0/1 (<i>n</i> = 150 [59.3%], 67 [53.6%] and 78 [62.9%]). Serum ustekinumab concentrations were comparable across groups. Proportions of patients experiencing treatment-emergent adverse events (TEAEs) were similar across groups; study medication–related TEAEs occurred in 14 (5.5%), 8 (6.4%) and 12 (9.7%) patients continuing CT-P43, continuing reference ustekinumab and switching, respectively. Switching did not increase antidrug antibody positivity. Results support the comparability of CT-P43 to reference ustekinumab. Efficacy was maintained after switching to CT-P43 from reference ustekinumab, without notable safety or immunogenicity findings.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04673786</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8811546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147299963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation”","authors":"","doi":"10.1155/dth/9813767","DOIUrl":"https://doi.org/10.1155/dth/9813767","url":null,"abstract":"<p>J. Y. Hong and K. Y. Park, “Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation,” <i>Dermatologic Therapy</i>, https://doi.org/10.1155/dth/8855222.</p><p>In the Funding section of the article, the statement “No funding was received for this research.” was incorrect.</p><p>This should have read:</p><p>“This work was supported by the Technology Innovation Program (or Industrial Strategic Technology Development Program-Material and Component Technology Development Project [Heterogeneous Technology Convergence Type] [20024946, Development of Tissue Regenerative Biosurgery Convergence Medical Products Using High-Functional Implantable Biomaterials]) funded by the Ministry of Trade, Industry &amp; Energy (MOTIE, Korea).”</p><p>We apologize for this error.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9813767","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147320938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arnebia euchroma Root Ointment for Pressure Ulcer Healing: A Double-Blind Randomized Controlled Trial","authors":"Armaghan Kazeminejad,&nbsp;Ebrahim Salehifar,&nbsp;Zahra Faghih,&nbsp;Mohammad Malekan,&nbsp;Amirreza Espahbodi,&nbsp;Mohtaram Andalib,&nbsp;Masoomeh Abdi Talarposhti,&nbsp;Nasim Gholizadeh","doi":"10.1155/dth/8929348","DOIUrl":"https://doi.org/10.1155/dth/8929348","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although various therapies are available for pressure ulcers, no single treatment has demonstrated superior effectiveness compared to others. <i>Arnebia euchroma</i> exhibits anti-inflammatory properties that facilitate the healing of surgical wounds and burns. We aimed to evaluate the efficacy of <i>A. euchroma</i> root ointment for the treatment of pressure ulcers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This double-blind randomized controlled trial included 20 patients with Stage I–III pressure ulcers from nursing homes and medical facilities in Sari, Mazandaran, Iran, in 2020-2021. Patients were randomly assigned to two groups: Patients in the intervention group received <i>Arnebia euchroma</i> root 5% ointment, while those in the control group received silver sulfadiazine 1%. The primary outcome was improvement in the diameter and depth of the ulcer. Secondary outcomes were changed in the Pressure Ulcer Scale for Healing (PUSH) and side effects. Outcomes were assessed before intervention and then at one, two, three, and 4 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients in both groups were comparable in terms of age, sex, nutritional disorders, use of antibedsore mattress, disease duration, underlying diseases, pressure ulcer stage, and pain, as well as baseline ulcer diameter, depth, and PUSH score. After 4 weeks, the ulcer depth was significantly lower in the intervention group than that in the control group (<i>p</i> &lt; 0.001, standardized mean difference [SMD] = −2.43, 95% confidence interval [CI] −0.58; −1.23). Ulcer depth and diameter differences at other time points were not statistically significant. Mean PUSH scores did not differ significantly between groups at any time point. No side effects were observed in any of the patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>A. euchroma</i> root ointment can significantly reduce pressure ulcer depth after 4 weeks of application, with no significant effects on ulcer diameter and PUSH score. <i>A. euchroma</i> root ointment appears to be a safe treatment for pressure ulcers. These results need to be confirmed in larger randomized controlled trials.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Iranian Registry of Clinical Trials (IRCT): IRCT20170818035762N4</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8929348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147280939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Meta-Analysis","authors":"Haiyan Weng,&nbsp;Pengfei Cha,&nbsp;Yan Wan,&nbsp;Ying Chen,&nbsp;Lili Xu,&nbsp;Yang Chen","doi":"10.1155/dth/3919856","DOIUrl":"https://doi.org/10.1155/dth/3919856","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Androgenetic alopecia (AGA) is a chronic progressive disorder that may lead to permanent hair loss and associated psychosocial issues if left untreated. Although botulinum toxin (BTX) has been proposed as a potential therapeutic option for AGA, the evidence regarding its efficacy remains controversial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to evaluate the efficacy of BTX monotherapy for AGA through a systematic review and meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search of PubMed, Embase, and the Cochrane Library to identify randomized controlled trials (RCTs) utilizing BTX for AGA treatment. The primary outcome was hair density (hair count/cm²).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 7 studies involving 232 treatment units were included. The pooled within-group change showed a mean increase of 24.51 hairs/cm² (95% CI: 10.22, 16.76) following BTX treatment. Subgroup analyses indicated that a significant increase in hair density was observed after 6 months of treatment, with an optimal injection dose of 100 U. Reinjection every 6 months was associated with significant hair density improvement. In addition, male participants demonstrated a more pronounced increase in hair density compared to mixed-gender cohorts (<i>p</i> = 0.0003). The therapeutic effect of BTX was more reliably estimated in studies with larger sample sizes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BTX monotherapy yielded significant within-group improvements in hair density and diameter among AGA patients. Subgroup analyses indicated that 100 U dosing with 6-month intervals may optimize therapeutic outcomes. These findings warrant validation in large-scale, randomized, placebo-controlled trials to establish definitive clinical utility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3919856","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study”","authors":"","doi":"10.1155/dth/9795863","DOIUrl":"https://doi.org/10.1155/dth/9795863","url":null,"abstract":"<p>T. Torres, A. Martorell, P. L. Felipe, et al., “Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study,” <i>Dermatologic Therapy</i> 2025, (2025): 7529636, https://doi.org/10.1155/dth/7529636</p><p>In the article, there was an error in the order of the last two authors. The author list has now been corrected in the article. The corrected author list is as follows:</p><p>Tiago Torres, Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, José Pardo, Ricardo Ruiz-Villaverde, Miquel Ribera</p><p>We apologize for this error.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9795863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Effect of Oral Tranexamic Acid on Hair Melanin in Asian Women”","authors":"","doi":"10.1155/dth/9839203","DOIUrl":"https://doi.org/10.1155/dth/9839203","url":null,"abstract":"<p>Zhang, T., Li, J., Li, Y., Guo, Z., &amp; Qi, X. (2025). Effect of Oral Tranexamic Acid on Hair Melanin in Asian Women. <i>Dermatologic Therapy</i>, 2025(1), 9071909. https://doi.org/10.1155/dth/9071909.</p><p>We apologize for these errors.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9839203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147268907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}